倒计时10天 | BIOHK2026脑机接口分论坛最新议程速递

美国加州大学旧金山分校（University of California, San Francisco, UCSF）生理学系荣休教授，同时也是神经科技创业者，在脑机接口（Brain-Computer Interface, BCI）、神经调控和神经工程领域具有国际影响力。

Sabes 教授于麻省理工学院（MIT）获得博士学位，研究方向为机器学习与人类运动控制，随后在加州理工学院（Caltech）和索尔克生物研究所（Salk Institute）开展神经生理学博士后研究。2000年加入UCSF并建立 Sabes Lab，长期致力于研究感觉—运动系统中的神经计算机制，以及先进脑机接口技术开发。

Sabes 教授团队在人工感觉反馈、灵长类脑接口和柔性电极植入技术等方向取得重要突破，开发了首个厘米尺度灵长类光遗传接口系统，并与加州大学伯克利分校 Maharbiz 实验室合作提出“缝纫机式”（Sewing-machine）柔性电极植入技术，为深部脑区高密度神经信号采集提供了关键技术路径。

2016年前后，Philip Sabes 教授受邀参与组建 Neuralink 创始团队，并于2017年全职投入脑机接口产业化工作。在 Neuralink 期间，团队进一步完善机器人辅助柔性电极植入技术，实现超过1000通道的高密度神经接口和全植入式无线脑机接口系统。

离开 Neuralink 后，Sabes 教授持续聚焦神经调控与疾病治疗方向。2020年共同创立 Starfish Neuroscience，致力于非侵入式神经调控、新一代植入式脑接口及精准脑调控技术。目前，他创办 Integral Neurotechnologies，旨在开发面向精神疾病和神经系统疾病治疗的新型脑接口技术，推动脑机接口从基础研究走向临床应用。

Philip Sabes 教授是全球脑机接口领域少数兼具顶尖神经科学研究背景、核心技术原创能力、大规模脑接口产业化经验及神经科技创业实践经验的代表性科学家之一。

现任香港理工大学生物医学工程学系教授、香港研究资助局高级研究员、无创脑机接口研究中心主任、动物实验中心副主任；在医学超声技术领域拥有25年的研发经验，涵盖系统开发、信号/图像处理及生物医学应用等方向，担任2025年聚焦超声神经调控大会主席；持有十余项已获授权或已提交申请的中美专利，已发表超过250篇同行评审期刊论文及国际会议论文；作为项目负责人，在香港及中国内地主持多项科研项目，累计科研经费超过8000万港元。

Dr. LU Hanna works as Assistant Professor at the Department of Psychiatry, The Chinese University of Hong Kong (CUHK). Before joining in CUHK, Hanna was a registered Attending Psychiatrist in Guangzhou, China. From bedside to bench, Hanna was motivated by the strong interests in aging brain and started the journey of becoming a clinical neuroscientist. Centred with ageing brain and disease-modifying therapy, Hanna’s research interests include: (1) to apply novel neuromodulation techniques in preclinical populations; (2) based on imaging data, to construct computational models for guiding personalized interventions for cognitive decline and sleep disturbances; (3) to develop AI-driven biomarkers (e.g., brain age model) for predicting treatment response and disease progress at individual level. With the financial support from GRF, HMRF, CUHK grants and generous donations, the findings of her studies were published in renowned medical and neuroscience journals. Some of her studies have received the Gold Awards on the Asian Oceanian Congress of Neurology (2021), Healthy Longevity Catalyst Award (Hong Kong) (2023) etc.

Jonathan Berent "JB" is the Founder and CEO of NextSense, Inc., a spinoff of X, Google's Moonshot Factory, building EEG-powered earbuds that enhance sleep and unlock brain health at scale. After a decade leading sales and partnerships at Google and Oracle, JB pivoted in 2016 to pursue a lifelong belief that unlocking the mind is the key to human potential. His work at X grew into the lab's largest funded early-pipeline project by 2020. JB co-authors peer-reviewed sleep research, lectures regularly at Stanford and UCSF, and was featured on the cover of Wired in June 2022. He holds a BA with Honors in Philosophy & Religious Studies from Stanford University.

复旦大学教授，上海科技大学特聘教授，华山医院神经外科主任医师。上海市东方英才领军人才。专业领域含脑肿瘤精准外科，脑机接口，医学人工智能。上海市脑机接口临床试验与转化重点实验室主任，华山医院神经外科副主任，复旦大学神经外科研究所副所长，中国抗癌协会神经肿瘤专业委员会副主任委员，上海市政协委员。在研科技部颠覆性技术创新重点专项、“十四五”重点研发计划、国自然基金、国家社科基金重大项目等。他引6516次，H-index 47，在Nature Neuroscience、Nature Human Behaviour、Science Advances、Brain、Neuro-oncology、Neurosurgery、J Neurosurgery、CMJ等发表论文。获上海市科技进步一等奖、教育部科技进步一等奖、中华医学科技奖二等奖、上海市“银鸽奖”国际传播优胜出版奖等。

Professor Gilberto Leung is Tsang Wing-Hing Professors in Clinical Neuroscience at the University of Hong Kong (HKU). He graduated from the University of London with M.B.B.S. in 1992 and completed postgraduate training with the Hallett Gold Medal from the Royal College of Surgeons of England and the J. Douglas Miller Medal from the Royal College of Surgeons of Edinburgh. He joined HKU in 2005 where he obtained his MS, PhD, and MD degrees.

He is currently Director of the School of Clinical Medicine and Convenor of the Clinical Neuroscience Consortium at HKU; Immediate-Past President and Honorary Fellow of the Hong Kong Academy of Medicine; and Convenor of the Institute for Medical Advancement and Clinical Excellence (IMACE).

He holds an LLB from the University of London and an LLM in Medical Law and Ethics with Distinction from the University of Edinburgh. He is Co-Director of the Centre for Medical Ethics and Law at HKU and Chairperson of the Clinical Ethics Committee at Queen Mary Hospital, where he practises clinically as Honorary Consultant Neurosurgeon.

His research interests include endoscopic neurosurgery, neuro-oncology, and medical law and ethics, having published 231 peer-reviewed journal articles, three monographs, and 13 book chapters.

公共卫生医学专科医生，2009年毕业于香港中文大学医学院，其后取得香港医学专科学院院士(社会医学)；现为香港特别行政区政府卫生署医疗器械科高级医生，主要负责协助制定香港特区医疗器械监管立法建议的工作。

广东省智能科学与技术研究院研究员，于2019年获香港理工大学生物医学工程学博士学位；2019年至2022年，在斯坦福大学医学院从事博士后研究；曾在神经科学、生物物理学、生物医学工程及光学工程等领域的多个顶尖国际会议上获奖；国家自然科学基金委员会项目负责人，已提交六项中国发明专利申请及四项美国专利申请，研究成果发表于多本权威学术期刊；目前担任《STAR Protocols》期刊顾问委员会成员。

脑智天地·脑机接口科创转化中心主任，复旦大学类脑智能科学与技术研究院副院长，复旦大学神经调控与脑机接口研究中心主任，中国神经科学学会神经调控基础与转化分会主任委员，上海市神经科学学会神经调控分会主任委员，脑机接口产业联盟副理事长。2002-2007年在英国牛津大学生理系和功能神经外科从事博士后工作，2007-2012年为南安普顿大学任讲师，2012-2017年在中科院苏州生物医学工程技术研究所工作，2017年进入复旦大学。长期从事深部脑刺激、神经信息处理与建模，以及临床转化应用研究。

Fred Li, Managing Director and Head of University Ventures, has over 15 years of experience in private market transactions, management operations, and turnarounds as both a deal maker and a former General Manager. Fred holds a Bachelor of Business Administration in Accounting and Finance from the University of Hong Kong and a Master of Science in Biotechnology from the Hong Kong University of Science and Technology. He is a Certified Public Accountant (CPA) of HKICPA and Certified ESG Analyst (CESGA).

Fred began his career as a restructuring advisory specialist at Deloitte. Later, he gained full-cycle deal experience and served on the board of directors of portfolio companies during his positions at VC and PE firms, including Senior Associate at Ocean Equity Partners (MFO), Vice President at CITIC CLSA Capital Partners, and Executive Director at Hywin International. He also gained practical experience in business management, successful turnarounds, and digital transformation as Group General Manager at Gaia Group, a 1,000-person task force company in his previous portfolio.

He has served as the lecturer, advisory committee, vetting panelist, trainer, and mentor for ecosystem partners such as Hong Kong’s Universities, NUS, BIOHK, BIOCHINA, HKSTP and Cyberport. Fred has hybrid experience across technology and business strategy and operations, with a focus on university spin-offs, Healthcare & Biotechnology, AI+ and GreenTech.

脑智天地·脑机接口科创转化中心主任，复旦大学类脑智能科学与技术研究院副院长，复旦大学神经调控与脑机接口研究中心主任，中国神经科学学会神经调控基础与转化分会主任委员，上海市神经科学学会神经调控分会主任委员，脑机接口产业联盟副理事长。2002-2007年在英国牛津大学生理系和功能神经外科从事博士后工作，2007-2012年为南安普顿大学任讲师，2012-2017年在中科院苏州生物医学工程技术研究所工作，2017年进入复旦大学。长期从事深部脑刺激、神经信息处理与建模，以及临床转化应用研究。

心血管外科医生，从医逾20年，创立了江苏美凤力集团，专注于创新医疗器械的评价和临床推广，曾任第四军医大学西京医院心血管外科医生，美国马里兰大学助理教授，完成心脏手术4000余例，多次评为优秀医务工作者和教学先进个人；参与我国第一个生物心脏瓣膜项目，发表主要核心研究成果（33篇SCI），高端医疗器械研发相关21篇，专利14项；美国留学4年，负责人工心脏等多个高端医疗器械的临床前大动物实验，向美国FDA递交了多个人工心脏、人工心脏瓣膜的临床前研究报告。

Prof. Chan is the Founder of Brainsmart Technology Limited, an Associate Professor in the Department of Mechanical Engineering at the Faculty of Engineering, The University of Hong Kong, and Co-Director of the Advanced Biomedical Instrumentation Centre. He has long been engaged in research on micro/nano fabrication, flexible electronic components, and brain–computer interfaces, and possesses combined expertise in academic research, research management, and technology translation. He has received the Outstanding Young Researcher Award and the Research Output Award from the University of Hong Kong, and was also honoured with the Emerging Investigator Lectureship from the Royal Society of Chemistry's Physical Chemistry Chemical Physics (PCCP). He currently serves as a non-official member of the Committee on Artificial Intelligence plus (AI+) and Industrial Development Strategy, contributing his professional expertise to policy and strategic planning for AIdriven industrial transformation in Hong Kong.

Christoph Guger studied electrical and biomedical engineering at the University of Technology Graz in Austria and Johns Hopkins University in the USA and received his PhD in 1999. In 1999 he started the company g.tec which has now branches in Austria, Spain, the USA, Canada and Hong Kong and India. g.tec produces high-quality neurotechnology and real-time brain computer interfaces for the research, medical and consumer market. The company is active in many international research projects about brain-computer interfacing, neuromodulation, stroke rehabilitation, assessment and communication with patients with disorders of consciousness and high-gamma mapping in epilepsy and tumor patients.

Ludovic is a Medtech entrepreneur and microengineering specialist dedicated to transforming healthcare through advanced neurotechnology. With a PhD in microsystems and microelectronics and many years of experience spanning the biotech and medtech sectors, he is the Co-founder of Neurosoft Bioelectronics. Driven by a mission to help patients with debilitating neurological disorders, his company pioneers ultra-soft, bio-integrable neural implants.

Unlike many other technologies, these minimally invasive implants can safely interface with large brain areas. This unique capability overcomes the limitations and risks of traditional rigid devices, making Neurosoft's technology specially positioned to create more precise and deliberate Brain-Computer Interfaces (BCIs). By capturing high-fidelity, large-scale neural data across the full cortex, this innovation also provides the essential data layer for Neurosoft's brain AI. It enables the training of advanced cortical foundation models that dramatically improve brain decoding, unlocking new frontiers for scalable therapeutics and bringing tangible hope to patients.

傲意科技脑科学事业部总监，毕业于复旦大学，脑科学博士，前脑虎科技产品负责人。10+年脑机接口研究开发工作，多家人工智能和脑机接口创业企业任职经历。主导研发了多款侵入和非侵入的产品，包括医疗级以及智能可穿戴产品，覆盖监测和调控，应用于康复、评估以及临床治疗的多个场景。产品曾荣获上海“白玉兰”，“上海设计100+”等奖项。

神经科学家和神经科技领域高管，致力于脑机接口（BCI）、神经调控以及人机交互领域的前沿研究与技术转化；曾任Neuralink临床合作负责人，并曾在美国南卡罗来纳医科大学创立并领导Neuro-X实验室及计算脑成像核心平台，研究涵盖聚焦超声、神经解码、脑刺激、神经影像及临床转化等领域；目前担任 Gestala 副总裁兼临床与科学负责人，领导公司非侵入式超声神经技术的临床与科学研发，致力于以不断提升的精准度和可扩展性实现与人脑的交互。

拥有超过25年的私募股权投资及生命科学产业经验，累计领导投资金额超过10亿美元。其主导的多个医疗健康跨境投资及并购项目曾荣获“最佳私募股权投资案例TOP10”等行业奖项。

在创立蓝海资本之前，杨锋先生曾任建银国际董事总经理及医疗基金负责人，并曾在PPF集团负责中国战略投资，参与创建捷信中国；亦曾于TPG（德州太平洋集团）工作。

杨锋先生长期专注于生物医药创新、脑科学、脑机接口及跨境医疗投资合作，积极推动中国创新药企国际化发展。其带领蓝海资本成为中国首批加入联合国负责任投资原则（UN PRI）的专业医疗投资机构之一。

杨锋先生拥有香港科技大学MBA学位，并曾于哥伦比亚大学商学院及德国HHL莱比锡商学院交流学习。

Steven has spent more than 17 years in the financial industry, starting as an equity analyst at Chinese Investment Bank Haitong Securities. He later advanced the path as director of asset management at CCB International and managing director at GBA Development Fund (A PE firm in Hong Kong with an AUM of 2 Billion USD) before founding his ventures in 2023. Steven graduated from Xi’an Jiaotong University and University of Hong Kong, He also holds MBA degree from University of Cambridge.

In parallel, he pursued academic interests in mathematics and Artificial Intelligence, and has raised over £2m for Cambridge University and therefore been named as a fellow at Clare Hall Cambridge.

美国哥伦比亚大学硕士，香港大学MBA，持有中国香港证监会1、4、9号牌照，香港数字资产业协会会员，上海长三角科创投资促进会会员，中国机器人产业联盟联合发起会员。曾在多家头部金融机构参与投融资项目超200亿元，主导了强脑科技、壁仞科技、智谱、曦望等多个高科技领域的投资。